RxDoctor Payments Data

Daniel Brewer

Psychiatric/Mental Health · Fort Wayne, INNPI 1205497401

Payments from drug & device makers

$907in general payments, 2019–2025

Across 34 payments — averaging $26.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$396
  • Otsuka America Pharmaceutical, Inc.$386
  • AbbVie$31
  • Takeda Pharmaceuticals U.S.A., Inc.$29
  • Neurocrine Biosciences, Inc.$29
  • Alkermes, Inc.$25
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$907100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$907 in reported general payments places this provider in the 55th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$14,600
Medicare patients
56
Services billed
163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate60$193,874
RexultiBrexpiprazole65$95,203
VraylarCariprazine Hcl47$68,523
TrintellixVortioxetine Hydrobromide89$52,603
Risperdal ConstaRisperidone Microspheres33$41,729
Risperidone ErRisperidone Microspheres30$30,849
LatudaLurasidone Hcl12$25,912
Lurasidone Hcl45$15,059
FanaptIloperidone14$14,067
Clozapine78$7,578
Aripiprazole79$7,276
Paliperidone ErPaliperidone14$6,751
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl36$3,332
Atomoxetine Hcl22$3,068
Quetiapine Fumarate112$2,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$386$95,20365 claims
AbbVieVraylar$31$68,52347 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$29$52,60389 claims
Sunovion Pharmaceuticals Inc.Latuda$396$25,91212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →